Notice of Availability of Administrative Supplements for Secondary Analysis of Existing Datasets within the Rare Diseases Clinical Research Network (RDCRN) to Explore Outcomes Relevant to Rare Diseases

Notice Number: NOT-TR-18-019

Key Dates
Release Date: April 25, 2018

Related Announcements

Issued by
National Center for Advancing Translational Sciences (NCATS)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute on Dental and Craniofacial Research (NIDCR)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute of Neurological Disorders and Stroke (NINDS)


The National Center for Advancing Translational Science (NCATS) announces the opportunity for investigators with relevant active Rare Diseases Clinical Research Consortia (RDCRC) for Rare Diseases Clinical Research Network (RDCRN) (U54) to submit administrative supplement requests to the NIH Parent Funding Opportunity Announcement (FOA), Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) PA-18-591 .

It is vitally important to begin to use the existing RDCRC datasets as they are intended: through secondary analyses to develop new hypotheses about Rare Diseases outcomes; such as identify particular vulnerabilities in specific populations; explore age, sex or racial differences that may warrant larger studies; discover new treatment/rehabilitation approaches; and reveal correlations among outcomes or outcome domains that can guide future studies.

The goal is to use existing human datasets for well-focused secondary analyses to investigate novel scientific ideas or new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the RDCRN’s mission. RDCRN's mission is to foster development of scientific knowledge needed to enhance the health, productivity, independence, and quality-of-life of individuals with Rare Diseases.

Program Director(s)/Principal Investigators (PIs) are strongly encouraged to partner with Early Stage Investigators (ESIs). Projects must not propose to collect new data and must be within scope of the current award.

Budget and Available Funds

Budgets are limited to no more than $50K in direct costs.

Award Project Period

Supplement project and budget periods are limited to the remaining FY18 budget period. To be eligible, the parent award must be active (i.e. not be in an extension period), and the research proposed in the supplement must be accomplished within the remaining active budget period that started in FY18 for the existing parent award. The earliest anticipated start date is July 1, 2018.

Review process

The Administrative Review will be conducted by a committee of NIH RDCRN Program Officers/Program Directors with final decisions made by the funding ICs

Page Limit

NCATS will consider supplements with a Research Strategy of no more than 3 pages.

Submitting an Application

Applicants should begin their application by stating: This application is being submitted in response to NOT-TR-18-019". For additional information, see the parent program announcement to Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) PA-18-591.

Applications for these administrative supplements are due by 5:00 PM local time on June 8, 2018.


Please direct all inquiries to:

Tiina K. Urv, PhD
National Center for the Advancement of Translational Science (NCATS)
Telephone: 301-827-2746